INDIANAPOLIS--(BUSINESS WIRE)-- Positron Corporation (OTCBB:POSC) (the “Company”) a molecular imaging solutions company focused on Nuclear Cardiology, announced the highlights from the Company’s presentation before NASDAQ on May 5, 2010.
The Management of Positron Corporation introduced the Company at the NASDAQ Marketsite. This forum is of great value to Positron since it provides broad exposure and access to a far reaching investment community.
The Company set out to explain the foundation of its business, the confirmation of a strategic partnership and potential revenue. Management discussed most all aspects of the Company’s plans which it was at liberty to disclose. A transcript of the presentation will be filed with the Securities and Exchange Commission on a Form 8-K immediately when it becomes available in coming days.
Positron representatives did confirm an agreement with an industry leading strategic partner that will give the Company the ability to greatly expand the Company’s revenue stream and our position in the molecular imaging market by offering imaging systems and radiopharmaceutical distribution. Patrick Rooney, Positron Corporation’s CEO states, “We would have liked to introduce a certain synergistic business partner as was stated in the press; however it was the recommendation of both companies to not disclose further details due to a potential expansion relationship and certain strategic competitive advantages. We anticipate additional information will be disclosed in the near future.”
Positron also gave guidance as to its target revenue. Based on the Company’s research and unique positioning in the marketplace, Positron projects significant sales growth quarter over quarter, year over year. Positron projects that in the next 5 years the nuclear cardiology market will approach $1.5 Billion in revenue annually. The projections reflected sales from Positron’s PET device and radiopharmaceutical devices and services. Positron may potentially achieve greater revenue as it expands into new markets with broader indications that we expect will be fully supported by Medicare and private payers.
About Positron: Positron founded in 1983, is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. Positron is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317) 576-0183.
CONTACT:
Positron Corporation
Patrick Rooney
(317) 576-0183
KEYWORDS: United States North America Indiana New York
INDUSTRY KEYWORDS: Health Cardiology Medical Devices Radiology
MEDIA: